Overall, vanzacaftor–tezacaftor–deutivacaftor had a similar effect on lung function as elexacaftor–tezacaftor–ivacaftor, with the potential to result in greater improvements in CFTR function in a broader population of people with cystic fibrosis. The gene discussed is CFTR; the disease is cystic fibrosis.